体外循环心脏手术中镇痛与麻醉药物的药代与药效学:叙述性综述
该叙述性综述汇总22项研究,分析体外循环(CPB)对常用持续输注麻醉与镇痛药物药代动力学和药效学的影响。CPB启动时血液稀释与低温改变血浆总浓度和游离浓度,不同药物需差异化调整剂量;丙泊酚与瑞芬太尼的靶控输注(TCI)模型在CPB下不准确,不推荐使用。
要点
- CPB启动致血液稀释和低温,总血浆浓度下降而游离浓度升高,药物效应因药而异。
- 芬太尼与舒芬太尼CPB启动时血浆浓度平均降25%,舒芬太尼CPB后升近50%,需考虑追加负荷并降低维持量。
- 丙泊酚与七氟烷在CPB期间可能需更低剂量达到相同麻醉效应;瑞芬太尼低温时每降5°C输注速率应减30%。
核心结论
- CPB显著改变麻醉与镇痛药物的药代和药效学,剂量不准确可致不良事件,需重视个体化用药与客观监测。
研究设计与样本
- 叙述性综述,初筛197篇文章,最终纳入22篇,按药物主题分布为丙泊酚9篇、七氟烷4篇、瑞芬太尼3篇、异氟烷2篇、芬太尼2篇、舒芬太尼2篇、阿芬太尼1篇。
主要发现
- CPB启动通常致血液稀释和低温,总血浆浓度下降而游离血浆浓度升高。
- 丙泊酚和七氟烷在CPB期间可能需更低剂量达到相同麻醉效应。
- 芬太尼和舒芬太尼CPB启动时血浆浓度平均下降25%(因分布容积增加),CPB期间随后升高,舒芬太尼CPB后升高近50%。
- 瑞芬太尼CPB启动时血浆浓度下降,常温患者应考虑更高初始或调整维持剂量;低温条件下每降5°C输注速率应减少30%。
- 阿芬太尼CPB期间总血浆浓度下降而游离分数不变,无需进一步调整。
关键数值与推荐
- 丙泊酚(Schnider、Marsh和PGIMER)与瑞芬太尼(Minto)的TCI模型在CPB背景下不准确,基于纳入研究不推荐使用。
- 芬太尼与舒芬太尼:CPB启动时血浆浓度平均降25%,舒芬太尼CPB后升近50%,提示CPB前考虑追加负荷并降低维持剂量以避免镇静延长。
- 瑞芬太尼:低温时每降5°C输注速率减少30%;常温患者考虑更高初始或调整维持剂量。
临床怎么用
- CPB期间应结合患者特异性因素和客观监测工具调整麻醉与镇痛药物剂量。
- 芬太尼/舒芬太尼在CPB前可考虑追加负荷,CPB后降低维持剂量以防镇静延长。
- 瑞芬太尼在低温时按每降5°C减30%输注速率,常温时考虑增加剂量。
- 避免在CPB期间依赖丙泊酚(Schnider、Marsh、PGIMER)和瑞芬太尼(Minto)TCI模型。
局限性
- 本文为叙述性综述,纳入研究数量有限(22篇),各药物研究分布不均。
- CPB后药物反应改变的临床意义在高危人群中仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiopulmonary bypass (CPB) impacts pharmacokinetics and -dynamics of drugs used during cardiac surgery. These alterations can lead to changes in drug efficacy resulting in under- or overdosing. This review summarizes current knowledge on the effects of CPB on commonly used intraoperative and continuously administered anesthetics and analgesics. Out of 197 articles initially identified, 22 were included in the final review. The breakdown of studies by main topic was as follows: propofol (9 articles), sevoflurane (4), remifentanil (3), isoflurane (2), fentanyl (2), and sufentanil (2), and alfentanil (1). The initiation of CPB typically results in hemodilution and hypothermia, leading to a decrease in total plasma concentration combined with an increase in unbound plasma concentrations. This phenomenon has varying implications for different drugs: For propofol and sevoflurane, lower doses may be required during CPB to achieve the same anesthetic effect. Fentanyl and sufentanil plasma concentrations decrease by 25% on average at CPB initiation due to an increased volume of distribution, followed by an increase during CPB, with sufentanil, showing an almost 50% increase post-CPB. This implies that an additional bolus before CPB initiation should be considered, followed by a reduction of the maintenance dose to prevent prolonged sedation. Remifentanil plasma concentration decreases at CPB initiation, which implies that higher initial- or adjusted maintenance dose should be considered in normothermic patients. However, under hypothermic conditions, infusion rates should be decreased by 30% for every 5°C decrease in temperature. Alfentanils, total plasma concentration decreases during CPB, while its free fraction remains unaltered, indicating that no further adjustments are necessary. Target-controlled infusion (TCI) models for propofol (Schnider, Marsh, and PGIMER [Postgraduate Institute of Medical Education and Research]) and remifentanil (Minto) were found to be inaccurate in the context of CPB. Based on the included studies, the use of these pharmacokinetic models is not recommended. In conclusion, dosing inaccuracies resulting in adverse events in on-pump cardiac surgery underscore the importance of understanding the pharmacokinetics and -dynamics of anesthetic and analgesic drugs during CPB. The clinical implication of the altered drug responses after CPB remains challenging in this high-risk population. Key takeaways include the necessity of considering patient-specific factors, utilizing objective monitoring tools, and recognizing potential drug alterations due to CPB.
引用
- Beukers A, Breel J, van den Brom C, et al. Pharmacokinetics and Pharmacodynamics of Analgesic and Anesthetic Drugs in Patients During Cardiac Surgery With Cardiopulmonary Bypass: A Narrative Review. Anesth Analg. 2025. PMID: 40378083. doi:10.1213/ANE.0000000000007564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。